The evidence on peptides — delivered weekly. Subscribe free →

Cortagen

unknown risk

Also: Ala-Glu-Asp-Leu · Cardiogen homolog

Preliminary Research Only

Cortagen is a synthetic tetrapeptide from the Russian Khavinson bioregulator series, derived from cardiac tissue. It is purported to have cardioprotective and longevity-promoting effects based on animal and limited human studies.

Molecular Weight
435.4 g/mol
Formula
C18H29N4O8
Common Dosing
5-10 mg/day for 10-day courses (from Russian literature)
Category
research
Last Reviewed
2025-01-15

Reported Benefits

Cardiovascular Protection

Preliminary 8 studies

Animal studies show reduced cardiac damage after ischemia.

Longevity

Preliminary 5 studies

Studies in aged animals suggest improved survival rates.

Mechanism of Action

Cortagen is proposed to modulate cardiac gene expression through nuclear penetration, activating cardioprotective pathways and reducing age-related gene expression changes in cardiac tissue.

Key Clinical Studies

Khavinson VKh (2010)

animal · Aged rats

Improved cardiac function and lifespan with cortagen

Overview

Cortagen is the cardiovascular member of the Russian short peptide bioregulator series. Like its family members (thymalin for immune, epithalon for pineal/aging, pinealon for neural), it is derived from the target organ tissue and purported to specifically regulate gene expression in that tissue.

Evidence Context

The evidence base shares the limitations of the broader Khavinson research tradition: primarily animal studies from a single laboratory, with some human pilot data of uncertain methodological quality. Independent Western replication is lacking.

Cardioprotection Mechanism

The proposed mechanism — nuclear penetration and chromatin/gene expression modulation — is consistent across the bioregulator peptide series. Whether this represents a genuine tissue-specific gene regulatory mechanism or a non-specific effect requires more rigorous investigation.

Comparative Context

Cortagen has less evidence than SS-31 (elamipretide), which has also demonstrated cardioprotection but through a much better-characterized mitochondrial mechanism and with Phase 2 human trial data.

Regulatory Status

Research Only

Russian bioregulator; no FDA/EMA approval

Safety Profile

Side Effects

  • Injection site reactions

Contraindications

  • Active cardiac disease (use only under medical supervision)

Drug Interactions

  • Cardiac medications

Primary Uses

Cardiovascular protectionHeart agingLongevityCardioprotection

Related Peptides

Weekly Briefing

Regulatory updates + new study breakdowns.

For Practitioners

Do you prescribe Cortagen?

Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.

Get Listed →
Disclaimer: This information is for educational and research purposes only. Not medical advice. Consult a qualified healthcare provider before using any compound.